Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-Increased serum CIIM in subjects with severe radiographic osteoarthritis
Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-Increased serum CIIM in subjects with severe radiographic osteoarthritis
复制标题
DOI：
10.1016/j.clinbiochem.2011.01.001
复制
发表时间：
2011-04-01
影响因子：
2.8
通讯作者：
Karsdal, Morten A.
中科院分区：
文献类型：
--
作者：
Bay-Jensen, Anne-Christine;Liu, Qi;Karsdal, Morten A.
目的：在关节退行性疾病中，胶原被基质金属蛋白酶降解，蛋白片段被释放到血清中作为潜在的生物标志物。RDGAAG（1053））。开发了针对新表位的两种ELISA。在存在或不存在蛋白酶抑制剂的情况下，在软骨外植体中测量CIIM。在OA滑液（n = 51）和血清（n = 156）中测量CIIM。结果：ELISA技术性能良好，CV%<13%。从软骨外植体的CIIM释放被MMP抑制剂阻断。在滑液中检测到CIIM。此外，轻度或重度OA患者的血清CIIM水平显著高于无OA患者（P < 0.05）。结论：我们开发了一种新的关节退行性疾病生物标志物，我们证明其来源于MMP降解的II型胶原：（C）2011年加拿大临床化学家协会。爱思唯尔公司出版All rights reserved.
Objectives: In joint degenerative diseases, the collagens are degraded by matrix metalloproteinases and protein fragments are released to serum as potential biomarkers.Methods: A collagen type II specific neoepitope, CIIM, was identified (... RDGAAG(1053)) by mass spectrometry. Two ELISAs against the neoepitope were developed. CIIM was measured in cartilage explants in the presence or absence of protease inhibitors. CIIM was measured in OA synovial fluid (n = 51) and serum (n = 156). Knee OA was graded by standard Kellgren-Lawrence (KL) score.Results: The ELISAs showed good technical performance: CV%, < 13%. CIIM release from cartilage explants was blocked by the MMP inhibitor. CIIM was detected in synovial fluid. Furthermore, serum CIIM levels were significantly higher (P < 0.05) in those individuals with mild or severe OA than in those with no OA.Conclusion: We developed a new biomarker for joint degenerative diseases, which we demonstrated was derived from MMP-degraded type II collagen: (C) 2011 The Canadian Society of Clinical chemists. Published by Elsevier Inc. All rights reserved.